KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Long-Term Deferred Tax (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 14 years of Long-Term Deferred Tax data on record, last reported at $846.2 million in Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax rose 45.09% year-over-year to $846.2 million; the TTM value through Sep 2025 reached $846.2 million, up 45.09%, while the annual FY2024 figure was $560.2 million, 17.25% up from the prior year.
  • Long-Term Deferred Tax reached $846.2 million in Q3 2025 per JAZZ's latest filing, up from $602.9 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $846.2 million in Q3 2025 and bottomed at $258.5 million in Q1 2021.
  • Average Long-Term Deferred Tax over 5 years is $447.3 million, with a median of $430.1 million recorded in 2023.
  • Peak YoY movement for Long-Term Deferred Tax: increased 0.1% in 2022, then skyrocketed 47.43% in 2023.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $311.1 million in 2021, then grew by 20.94% to $376.2 million in 2022, then rose by 27.0% to $477.8 million in 2023, then rose by 17.25% to $560.2 million in 2024, then soared by 51.04% to $846.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $846.2 million in Q3 2025, $602.9 million in Q2 2025, and $575.1 million in Q1 2025.